Cribstone Capital Management LLC bought a new position in Humana Inc (NYSE:HUM) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 865 shares of the insurance provider’s stock, valued at approximately $230,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Moody National Bank Trust Division bought a new stake in Humana during the fourth quarter worth about $30,000. We Are One Seven LLC bought a new position in Humana during the fourth quarter valued at $31,000. Proficio Capital Partners LLC raised its stake in shares of Humana by 81.4% in the fourth quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 48 shares during the period. Exane Asset Management purchased a new position in Humana in the 4th quarter worth about $43,000. Finally, Sontag Advisory LLC purchased a new position in Humana in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 94.52% of the company’s stock.
A number of analysts recently commented on HUM shares. JPMorgan Chase & Co. upgraded shares of Humana from a “neutral” rating to an “overweight” rating and set a $283.00 target price for the company in a research note on Thursday, December 20th. Barclays reissued a “buy” rating and set a $351.00 price target on shares of Humana in a research report on Sunday, January 6th. Zacks Investment Research restated a “hold” rating and issued a $306.00 price objective on shares of Humana in a report on Monday, December 31st. Citigroup cut their target price on shares of Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a research note on Thursday, February 7th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $325.00 price target on shares of Humana in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the stock. Humana presently has a consensus rating of “Buy” and an average price target of $355.06.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 6th. The insurance provider reported $2.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.53 by $0.12. The business had revenue of $14.17 billion for the quarter, compared to analyst estimates of $14.04 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. The firm’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the company earned $2.06 EPS. As a group, equities analysts expect that Humana Inc will post 17.49 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.20 dividend on an annualized basis and a yield of 0.84%. This is a boost from Humana’s previous quarterly dividend of $0.50. Humana’s dividend payout ratio (DPR) is presently 3.44%.
In other news, insider Roy A. Beveridge sold 8,278 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the completion of the transaction, the insider now directly owns 12,409 shares in the company, valued at $3,811,548.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher H. Hunter sold 15,586 shares of the business’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the completion of the sale, the insider now directly owns 28,100 shares in the company, valued at approximately $8,577,244. The disclosure for this sale can be found here. 0.54% of the stock is currently owned by insiders.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Debt-To-Equity Ratio
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.